From: Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Compound | IC50 | Development stage | Ref. |
---|---|---|---|
CGX1321 | 1.0 nM | Phase I (NCT03507998): Gastrointestinal tumors; Phase I (NCT02675946): Solid tumors | |
ETC-159 | 2.9 nM | Phase I (NCT02521844): Advanced solid tumors | [401] |
LGK974 | 0.1 nM | Phase I (NCT01351103): TNBC and other cancers | |
GNF-1331 | 12 nM | Preclinical | [402] |
GNF-6231 | 0.8 nM | Preclinical | [402] |
IWP2 | 27 nM | Preclinical | |
IWP-L6 | 0.5 nM | Preclinical | [405] |
IWP-O1 | 80 pM | Preclinical | [406] |
Porcn-IN-1 | 0.5 ± 0.2 nM | – | [407] |
Wnt-C59 | 74 pM | Preclinical | [398] |